Contact Us
Drug Search Results
More Filters [+]

Sarpogrelate

Alternative Names: sarpogrelate, mci-9042, anplag
Latest Update: 2024-11-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT2A Antagonist,GPIIb/IIIa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Korea

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sarpogrelate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Coronary Artery Disease|Peripheral Arterial Disease|Kidney Diseases|Myocardial Ischemia|Diabetic Nephropathy|Peripheral Vascular Diseases|Kidney Failure, Chronic|Thrombophilia|Angina Pectoris, Variant|Arterial Occlusive Diseases|Intermittent Claudication

Phase 3: Ischemic Stroke|Peripheral Arterial Disease|Peripheral Vascular Diseases|Coronary Artery Disease|Kidney Failure, Chronic

Phase 1: Healthy Volunteers|Peripheral Arterial Disease|Hypertension|Chronic Pain|Malnutrition

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SEUMC 2023-10-009

N/A

Not yet recruiting

Stroke|Intermittent Claudication|Atherosclerosis

2028-06-30

YMC047

P4

Completed

Peripheral Arterial Disease|Peripheral Vascular Diseases|Myocardial Ischemia|Coronary Artery Disease

2024-02-28

YMC044

P4

Completed

Intermittent Claudication|Arterial Occlusive Diseases

2023-03-09

DWAP_P401

N/A

Completed

Arterial Occlusive Diseases

2022-01-20

Recent News Events

Date

Type

Title

01/16/2024

PubMed

 Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model.

02/13/2023

PubMed

 A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions